Tresiba® (insulin degludec) (NN1250)

:Type 1 and 2 diabetes
:Filed for registration

A new-generation basal insulin with an ultra-long duration of action of more than 42 hours. Approved to offer patients reduced risk of hypoglycaemia and the possibility of adjusting the time of injection, when needed. Approved and launched in the EU, Japan and other markets. Additional data required by the US FDA are being generated for the planned resubmission.

Company announcements
Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014 (07 Aug 2014)
Novo Nordisk receives positive opinion on Xultophy® (IDegLira) from the European regulatory authorities (25 Jul 2014)
Increased operating profit in local currencies by 15% in the first quarter of 2014 (01 May 2014)
Read more company announcements

Press releases
Ryzodeg® provides successful glycaemic control with fewer injections than a basal-bolus regimen (18 Sep 2014)
New data show long-term efficacy and safety of Tresiba® in children and adolescents with type 1 diabetes (16 Sep 2014)
Mexico first country to launch Ryzodeg® (01 Sep 2014)
Read more press releases

Scientific abstracts
Advances in Therapy (2013)
Biochemistry (2013)
Clinical Drug Investigation (2013)
Read more scientific abstracts

You can search for more clinical trials on http://clinicaltrials.gov
  •